



Performance

28/02/2025 Monthly report

Investment objective and approach

Sources: ELEVA Capital

 Aiming to achieve an absolute return over the medium term through capital growth

• Investing primarily in European equities and equity related securities on both a long and short basis

• Differentiated and disciplined bottom up investment philosophy complemented by a macroeconomic overlay to support sector positioning

• Flexible net exposure between -10 and +50% driven by fundamental idea generation and market volatility

• Recommended investment horizon : ≥ 5 years

Key figures

Net Asset Value	148.56€
Total Fund Assets	4 347 792 641 €

Risk Indicator



Fund characteristics

Manager: Eric Bendahan Legal structure: Luxembourg SICAV - UCITS Fund launch date: 30/12/2015 Share class launch date: 08/03/2017 ISIN Code: LU1331971769 Bloomberg Ticker: ELEA1EA LX Classification: European Long/Short Equity Reference currency: EUR Distribution policy: Accumulation Valuation frequency: Daily

Administrative information

Custodian: HSBC Continental Europe, Luxembourg Fund admin: HSBC Continental Europe, Luxembourg Management company: ELEVA Capital SAS Subscription / redemption cutoff: 12:00 CET Subscription / redemption settlement: T+2

Fees

Subscription fees: Up to 3% Redemption fees: 0% Management fees: 2% Performance fees: 20% of any excess return the NAV achieves over the High Water Mark

Contact

Axel Plichon, Head of Business Development axel.plichon@elevacapital.com

This document should be read in conjunction with the prospectus and relevant KIDs which are available on our website www.elevacapital.com.

Past performance is no guarantee of future results. The UCITS Fund does not benefit from any guarantee or protection, so the initial invested capital may not be fully repaid.



Calendar year performance

	-		-				-	-		1	-		
	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2025	1.47%	-0.18%											1.28%
2024	0.49%	2.04%	1.75%	-0.30%	0.47%	0.91%	0.49%	0.33%	-0.12%	-0.40%	1.29%	0.47%	7.63%
2023	3.32%	0.20%	-0.75%	0.50%	0.49%	0.05%	-0.85%	0.06%	-0.56%	-1.00%	2.46%	0.75%	4.67%
2022	-2.27%	-1.15%	0.94%	0.05%	-1.66%	-0.60%	1.65%	-0.69%	-1.23%	1.14%	1.98%	-0.28%	-2.18%
2021	-1.00%	1.35%	-0.39%	0.43%	0.13%	0.50%	0.96%	0.73%	-0.02%	1.76%	0.03%	0.89%	5.48%
2020	-0.73%	-0.44%	-1.50%	2.33%	2.35%	1.56%	0.89%	2.15%	0.46%	-1.22%	0.27%	1.49%	7.77%
2019	2.58%	0.78%	0.36%	1.23%	-1.67%	0.28%	1.19%	0.76%	-0.59%	0.56%	1.61%	0.45%	7.72%
2018	1.87%	-1.37%	-0.48%	0.49%	1.93%	0.93%	0.22%	-0.33%	1.68%	-2.45%	-1.17%	-1.50%	-0.29%
2017				1.67%	1.37%	-0.24%	1.76%	0.60%	0.72%	2.35%	-0.58%	0.74%	8.68%

Monthly Comment

European markets rallied in February helped by better-than-expected results across the board and increased expectations of an end to hostilities in Ukraine. Inflows into European equities helped sustain the outperformance of the asset class. However, an announcement of tariffs for European goods continues to be a possibility. ELEVA Absolute Return Europe was down 0.18% this month.

The long book had a positive impact on performance but materially underperformed the move in relevant indices. Financials, industrials and consumer discretionary were the main drivers of performance. Conversely, the technology, health care and communication services allocations were a drag. The lack of pure play defense names also hindered performance.

Rolls Royce had a very strong set of results and materially upgraded their free cash flow expectations in the short term and also in 2028. **Siemens** also positively surprised on their key Smart Infrastructure division, highlighting a potential turnaround in automation orders after a period of weakness. Banks (**Barclays, Commerzbank, Intesa San Paolo**) continued to rally with positive comments and upgrades in their capital return expectations. Unfortunately, we were too defensive in our financial allocation (with insufficient exposure) and stock picking was detrimental this month.

BE Semiconductor Industries disappointed on its outlook, with a lack of short-term recovery in its base business despite long term interest in their hybrid bonding solutions. **Capgemini** had disappointing guidance after two average years. **Publicis** delivered good results but was affected by profit warnings from peers.

The short book had a negative impact on performance, with index hedges and single name shorts costing performance. Health care, consumer discretionary and technology were positive drivers of the short book performance. Nevertheless, it was not enough to compensate for the fall in index hedges, financials, communication services and energy.

Economic growth was decent in 2024, with low growth in Europe and in China balanced by an acceleration in the US. Falling inflation expectations reduce the risks of a Central Bank mistake. The macro environment was deteriorating last year, but now we see a modest inflection in Europe and a more material one in the Global and US indicator. Patience is needed in Europe for interest rates to have an impact on economic activity. In that environment we believe that corporates will still be able to grow at a moderate pace.

Value and cyclicals in the long book decreased from 48.8% to 48.5% and from 54.5% to 50.2%. Net exposure decreased from 31.7% to 28.3% but gross exposure increased from 152.2% to 154.1%.


ELEVA Absolute Return Europe - Class A1

Portfolio analysis

Geographic breakdown (Net %)

28/02/2025 Monthly report

Sector breakdown (Net %)




Market Capitalisation (Long Book)



Company Siemens AG	Weight (%) 2.97%	Indexes and Companies EUX STOXX EUROPE 600 MAR25	Weight (%) 37.06%
Top 5 Long Holdings			Top 5 Short Holdings
	93.2%	Sortino Ratio (since inception)	1.5
		Sharpe ratio (since inception)	1.1
■ > 20 Mds €		Volatility (since inception)	4.07%
■ 5 Mds € - 20 Mds €		Equity Gross Exposure	154.08%
≤ 5 Mds €		Equity Net Exposure	28.34%
		Equity Short Exposure	62.87%
		Equity Long Exposure	91.21%
	5.8%	Indicator	Value
	1.0%		

Cie Financiere Richemont SA	2.76%	STXE 600 BANKS (EUR) PR	2.45%
SAP SE	2.64%	CME S&P500 EMINI FUT MAR25	1.75%
Novo Nordisk A/S	2.55%	STXE 600 INDUGD&SER € PR	1.00%
Barclays PLC	2.48%	HEALTH CARE COMPANY	0.82%

Net Exposure



Share class	Launch date	ISIN	Bloomberg Ticker	Distribution policy	NAV
A1 (EUR) dis.	30/04/2018	LU1543705369	ELAA1ED LX	Distribution	133.40
A1 (GBP) acc. Hdg	07/02/2017	LU1716218950	ELEA1UA LX	Accumulation	138.48
A1 (USD) acc. Hdg	07/03/2019	LU1331971926	ELARA1G LX	Accumulation	168.13
A1 (USD) acc. Unhdg	07/03/2019	LU1331971843	ELA1UAH LX	Accumulation	121.29



ELEVA Absolute Return Europe - Class A1

28/02/2025 Monthly report

Worst 3 ESG ratings

ESG data (long book)

Investment process




** Fundamental analysis, ESG analysis & valuation



Best 3 ESG ratings

Name	Sector	Country	ESG Score	Name	Sector	Country	ESG Score
ASML Holding NV	Technology	Netherlands	83	Shell PLC	Energy	United Kingdom	42
Schneider Electric SE	Industrials	France	81	Rolls-Royce Holdings PLC	Industrials	United Kingdom	53
National Grid PLC	Utilities	United Kingdom	80	HeidelbergCement AG	Materials	Germany	56
		Ū		2			

ESG Performances



	Growth in the number of employees	% women on the board	% Signatories of the United Nations Global Compact	Carbon intensity	Carbon footprint
Fund	94%	100%	100%	100%	100%
Initial universe	91%	98%	98%	98%	98%

Legal disclaimer

This document is distributed for information purposes only and is primarily intended for subscribers of the UCI(s) presented. This is by no means a marketing document, and can not be equated with a recommendation or investment advice. This document may not be copied, distributed or communicated, directly or indirectly, to another person without the express consent of Eleva Capital. The sources used to carry out this reporting are considered reliable, however Eleva Capital declines all responsibility for any omission, error or inaccuracy. Eleva Capital accepts no responsibility for any direct or indirect losses caused by the use of the information provided in this document. The information presented in this document is simplified, for more information please refer to the Key Information Document and the prospectus of the relevant UCI available on our website (www.elevacapital.com). The figures quoted relate to past years and past performance is not a reliable indicator of future performance.

In Switzerland, the prospectus and the Key Information Document(s), the articles of association, the annual and semi-annual reports can be obtained, free of charge, at the offices of the Swiss representative and paying agent, Société Générale Paris, Zurich Branch, Talacker 50, 8001 Zurich. Société Générale Paris is registered at the Commercial Registry of the Canton of Zurich under number CH-105.273.103 pursuant to the CISA and registered with FINMA in Switzerland.

